induction chemotherapy

Total Tumor Volume: A Superior Predictor of Survival and Chemotherapy Response in Colorectal Cancer Liver Metastases

By MedXY 09/20/2025

This study reveals that total tumor volume (TTV) more accurately predicts overall survival and response to induction chemotherapy than RECIST1.1 in colorectal cancer liver metastases, offering a promising tool for personalized treatment decisions.

Clinical Updates Oncology Radiology Specialties Wellness & Lifestyle

Induction vs Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial

By MedXY 09/12/2025

This phase 3 trial compares induction-concurrent chemotherapy with concurrent-adjuvant chemotherapy in high-risk N2 to N3 nasopharyngeal carcinoma, finding no significant difference in 3-year progression-free survival while highlighting distinct safety profiles.

Clinical Updates Oncology Radiology Specialties

Sequential Chemoradiotherapy vs Induction Plus Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Efficacy and Safety Insights from a Phase 3 Randomized Trial

By MedXY 08/23/2025

A multicenter phase 3 trial demonstrates that sequential chemoradiotherapy is noninferior to induction plus concurrent chemoradiotherapy for stage III/IVA nasopharyngeal carcinoma with fewer acute toxicities.

Oncology Radiology Specialties

Comparative Efficacy of Induction-Concurrent Versus Concurrent-Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial

By MedXY 08/23/2025

A phase 3 trial showed no significant difference in 3-year progression-free survival between induction-concurrent and concurrent-adjuvant chemoradiotherapy in treating high-risk N2-N3 nasopharyngeal carcinoma, with both regimens exhibiting manageable safety profiles.